الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 199 |  |  |
| | | from | 199 | | |
Abstract
plenty researches have studied the role of rodent’s bone marrow- mesenchymal stem cells in spinal cord injury (SCI), but limited researches scoped the light on the use of human umbilical-mesenchymal stem cells (HUMSCs). Aim of the study: The present study was aimed to investigate the effects of human umbilical mesenchymal stem cells transplantation by intravenous and intralesional delivery methods on the functional restoration and recovery of experimental spinal cord injury Sprague Dawely rat models. In addition to that, determine if increasing the dose of Wharton’s jelly mesenchymal stem cells required obtaining the best results in the process of spinal cord injury treatment. Methodology: Umbilical cords were collected. Wharton’s jelly was scraped off, cultured, isolated HUMSCs was immunophenotyped. Rats (n=40) were divided into 5 groups: Control group (SCI only), Sham group (SCI + intravenous administration of physiological saline solution (PSS)), IL group (SCI + intralesional administration of HUMSCs), IV1 group (SCI + intravenous administration of HUMSCs) and IV2 group (SCI + intravenous administration of double amount of HUMSCs divide by a time interval of a week). Day after surgery, 1x106 HUMSCs were transplanted on the 3 treated groups, but IV2 group took another dose after one week. Basso-Beattie-Bresnahan (BBB) locomotor rating scale was measured for 6 weeks. Results: HUMSCs were fibroblast like appearance and they were +ve for CD29, CD90 and –ve for CD45. BBB scale showed that from the first week to the six week there were significant improvement between the 3 treated groups as compared to control group (P<0.05), IV2 group showed the best BBB improvement with the smallest lesion then IV1 and IL groups respectively, while there were no significant difference between control group and sham group. Conclusion: HUMSCs are useful in subsequent motor recovery after SCI. Intravenous delivery is better than intralesional delivery, also increasing the HUMSCs dose may enhance the recovery process.